IV ALD403: Additional Phase Ib data

Additional data from a double-blind, U.S. Phase Ib trial in 163 patients with frequent episodic migraine who had an average of 9 headache days per month showed that a single 1,000 mg dose of IV ALD403 led to a significantly greater proportion of patients who achieved a 100% reduction in migraine days (11% vs. 0%, p<0.002), a 75% reduction in migraine days (26% vs. 7%, p<0.002) and a 50% reduction in migraine days (53% vs. 28%, p<0.001) vs. placebo over 6 months. Data were presented at the International Headache Society meeting in Valencia. Alder previously reported that ALD403 met the primary endpoint of reducing mean migraine days per month during weeks 5-8 vs. placebo (see BioCentury, April 28, 2014). ...